Patient Selection

Adult Patients

Select adult patients for WEGOVY treatment as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management based on the BMI values provided in Table 1. Table 1 presents a chart for determining BMI based on height and weight. BMI is calculated by dividing weight (in kilograms) by height (in meters) squared.

Table 1. BMI Conversion Chart

​Pediatric Patients Aged 12 Years and Older

​Select pediatric patients aged 12 years and older for WEGOVY treatment as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management based on the BMI values provided in Tables 1 and 2. Table 1 presents a chart for determining BMI based on height and weight. Table 2 presents BMI cut-offs for obesity in pediatric patients aged 12 years and older, determined based on the CDC age- and sex-specific growth charts.

​Table 2. BMI Cut-offs for Obesity by Sex and Age for Pediatric Patients Aged 12 Years and Older (CDC Criteria)

​

Important Monitoring and Administration Instructions

•

In patients with type 2 diabetes, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment [see Warnings and Precautions (5.4)].

•

Prior to initiation of WEGOVY, train patients on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations.

•

Inspect WEGOVY visually prior to each injection. Only use if solution is clear, colorless, and contains no particles.

•

Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals.

•

Administer WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without dose adjustment.

Recommended Dosage

Dosage Initiation and Escalation

•

In adults and pediatric patients aged 12 years and older, initiate WEGOVY with a dosage of 0.25 mg injected subcutaneously once weekly. Then follow the dose escalation schedule in Table 3 to minimize gastrointestinal adverse reactions [see Adverse Reactions (6.1)].

•

If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.

Table 3. Dosage Escalation Schedule

Maintenance Dosage

Adult Patients

•

The maintenance dosage of WEGOVY is 2.4 mg injected subcutaneously once weekly.

•

If patients do not tolerate the maintenance 2.4 mg once-weekly dosage, the dosage can be temporarily decreased to 1.7 mg once weekly, for a maximum of 4 weeks. After 4 weeks, increase WEGOVY to the maintenance 2.4 mg once-weekly dosage. Discontinue WEGOVY if the patient cannot tolerate the 2.4 mg dosage.

​Pediatric Patients Aged 12 Years and Older

•

​The recommended maintenance dosage of WEGOVY is 2.4 mg injected subcutaneously once weekly.

•

​If patients do not tolerate the maintenance 2.4 mg once-weekly dosage, the maintenance dosage may be reduced to 1.7 mg once weekly. Discontinue WEGOVY if the patient cannot tolerate the 1.7 mg dose.

Recommendations Regarding Missed Dose

•

If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible. If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.

•

If 2 or more consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.